For example, the AT-rich interactive domain 1A gene (ARID1A) is mutated in over 50% of ovarian clear cell carcinomas and ARID1A mutational status has been shown to correlate with response to an enhancer of zeste homologue 2 (EZH2) inhibitor. The gene discussed is ARID1A; the disease is ovarian clear cell cancer.